menu
    • menu
    [{"orgOrder":0,"company":"Imugene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"PD1-Vaxx","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Imugene \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Imugene \/ Not Applicable"},{"orgOrder":0,"company":"Imugene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"PD1-Vaxx","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Imugene \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Imugene \/ Not Applicable"},{"orgOrder":0,"company":"Imugene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"PD1-Vaxx","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Imugene \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Imugene \/ Not Applicable"},{"orgOrder":0,"company":"Imugene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"IMU-131","moa":"HER2\/NEU receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Imugene \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Imugene \/ Not Applicable"},{"orgOrder":0,"company":"Imugene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"IMU-131","moa":"HER2\/NEU receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Imugene \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Imugene \/ Not Applicable"},{"orgOrder":0,"company":"Imugene","sponsor":"Celularity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"CF33-CD19 Oncolytic Virus","moa":"CD19","graph1":"Oncology","graph2":"Preclinical","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Imugene \/ Celularity","highestDevelopmentStatusID":"4","companyTruncated":"Imugene \/ Celularity"},{"orgOrder":0,"company":"Imugene","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"Avelumab","moa":"HER2","graph1":"Oncology","graph2":"Phase II","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Imugene \/ Merck","highestDevelopmentStatusID":"8","companyTruncated":"Imugene \/ Merck"},{"orgOrder":0,"company":"Imugene","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"HER-Vaxx","moa":"HER2","graph1":"Oncology","graph2":"Phase II","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Imugene \/ MSD","highestDevelopmentStatusID":"8","companyTruncated":"Imugene \/ MSD"},{"orgOrder":0,"company":"Imugene","sponsor":"City of Hope","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"CF33-hNIS","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Imugene \/ City of Hope","highestDevelopmentStatusID":"6","companyTruncated":"Imugene \/ City of Hope"},{"orgOrder":0,"company":"Imugene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Blinatumomab","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Imugene \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Imugene \/ Not Applicable"},{"orgOrder":0,"company":"Imugene","sponsor":"RenovoRx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Oncolytic Virus Therapy","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Imugene \/ Imugene","highestDevelopmentStatusID":"3","companyTruncated":"Imugene \/ Imugene"},{"orgOrder":0,"company":"Imugene","sponsor":"Precision BioSciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"Azercabtagene Zapreleucel","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imugene","amount2":0.66000000000000003,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.66000000000000003,"dosageForm":"Infusion","sponsorNew":"Imugene \/ Imugene","highestDevelopmentStatusID":"7","companyTruncated":"Imugene \/ Imugene"},{"orgOrder":0,"company":"Imugene","sponsor":"NeoImmuneTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"Azercabtagene Zapreleucel","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Imugene \/ Imugene","highestDevelopmentStatusID":"4","companyTruncated":"Imugene \/ Imugene"},{"orgOrder":0,"company":"Imugene","sponsor":"MaxCyte","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Licensing Agreement","leadProduct":"Azercabtagene Zapreleucel","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Imugene \/ MaxCyte","highestDevelopmentStatusID":"7","companyTruncated":"Imugene \/ MaxCyte"},{"orgOrder":0,"company":"Imugene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Blinatumomab","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Imugene \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Imugene \/ Not Applicable"},{"orgOrder":0,"company":"Imugene","sponsor":"Kincell Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Agreement","leadProduct":"Azercabtagene Zapreleucel","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Imugene \/ Imugene","highestDevelopmentStatusID":"7","companyTruncated":"Imugene \/ Imugene"},{"orgOrder":0,"company":"Imugene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Azercabtagene Zapreleucel","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Imugene \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Imugene \/ Not Applicable"},{"orgOrder":0,"company":"Imugene","sponsor":"Precision BioSciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Licensing Agreement","leadProduct":"Azercabtagene Zapreleucel","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Imugene","amount2":0.23000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Imugene \/ Imugene","highestDevelopmentStatusID":"14","companyTruncated":"Imugene \/ Imugene"}]

    Find Clinical Drug Pipeline Developments & Deals by Imugene

    Menu

    Imugene

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Imugene

                            Australia arrow
                            2024 ACI Convention
                            Not Confirmed

                            Imugene

                            Australia arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azercabtagene Zapreleucel,Fludarabine Phosphate,Cyclophosphamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Three Complete Responses in Azer-Cel Allogeneic CD19 CAR T Phase 1b Trial for Blood Cancer

                            Details : Azercabtagene Zapreleucel (azer-cel), an allogeneic CD19 CAR T cell therapy being investigated relapsed/refractory diffuse large B cell lymphoma.

                            Brand Name : Azer-cel

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            September 03, 2024

                            Lead Product(s) : Azercabtagene Zapreleucel,Fludarabine Phosphate,Cyclophosphamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Imugene

                            Australia arrow
                            2024 ACI Convention
                            Not Confirmed

                            Imugene

                            Australia arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azercabtagene Zapreleucel

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Precision BioSciences

                            Deal Size : $227.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Precision Receives $13M in Proceeds from Imugene Convertible Notes

                            Details : Imugene assumed global rights to azer-cel for cancer, the ongoing clinical execution for PBCAR0191 (azercabtagene zapreleucel) in LBCL patients who have relapsed following autologous CAR T treatment.

                            Brand Name : PBCAR0191

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : $21.0 million

                            September 03, 2024

                            Lead Product(s) : Azercabtagene Zapreleucel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Precision BioSciences

                            Deal Size : $227.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Imugene

                            Australia arrow
                            2024 ACI Convention
                            Not Confirmed

                            Imugene

                            Australia arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azercabtagene Zapreleucel,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : Kincell Bio

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Imugene and Kincell Announce Strategic Manufacturing and Process Development Partnership

                            Details : Under the agreement, Kincell will manufacture Imugene’s Azer-cel (azercabtagene zapreleucel), an off-the-shelf (allogeneic) cell therapy CAR T drug, to support ongoing clinical trials.

                            Brand Name : PBCAR0191

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            April 16, 2024

                            Lead Product(s) : Azercabtagene Zapreleucel,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Kincell Bio

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Imugene

                            Australia arrow
                            2024 ACI Convention
                            Not Confirmed

                            Imugene

                            Australia arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CF33-CD19,Blinatumomab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Phase 1 onCARlytics Solid Tumour Trial Advances to Combination Arm Treatment

                            Details : onCARlytics (CF33-CD19) is a novel CD19 oncolytic virotherapy drug candidate, which is being evaluated for the treatment of patients with advanced solid tumors.

                            Brand Name : onCARlytics

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 11, 2024

                            Lead Product(s) : CF33-CD19,Blinatumomab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Imugene

                            Australia arrow
                            2024 ACI Convention
                            Not Confirmed

                            Imugene

                            Australia arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azercabtagene Zapreleucel,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : MaxCyte

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            MaxCyte Signs License with Imugene To Advance Cancer Immunotherapy Programs

                            Details : Imugene has obtained commercial rights to use MaxCyte’s technology and ExPERT platform to support azer-cel, a potential allogeneic CD19 CAR T product candidate for blood cancer treatment.

                            Brand Name : PBCAR0191

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            January 23, 2024

                            Lead Product(s) : Azercabtagene Zapreleucel,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : MaxCyte

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Imugene

                            Australia arrow
                            2024 ACI Convention
                            Not Confirmed

                            Imugene

                            Australia arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azercabtagene Zapreleucel,Efineptakin Alfa

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : NeoImmuneTech

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            NeoImmuneTech and Imugene Enter into Strategic Research Collaboration to Improve Cancer Treatments

                            Details : The collaboration aims to evaluate Imugene's allogeneic CAR T, azer-cel, in combination with NIT's proprietary immune T cell amplifier "Fc-fused recombinant human interleukin-7", NT-I7, for the treatment of cancer.

                            Brand Name : Azer-Cel

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            December 11, 2023

                            Lead Product(s) : Azercabtagene Zapreleucel,Efineptakin Alfa

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : NeoImmuneTech

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Imugene

                            Australia arrow
                            2024 ACI Convention
                            Not Confirmed

                            Imugene

                            Australia arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azercabtagene Zapreleucel,Fludarabine Phosphate,Cyclophosphamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : Precision BioSciences

                            Deal Size : $662.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Precision BioSciences Completes Strategic Transaction with Imugene for Azer-Cel in Cancer

                            Details : Imugene gains global rights to PBCAR0191 (azercabtagene zapreleucel), Precision’s lead allogeneic CAR T candidate, for cancer. Imugene will assume ongoing trial for azer-cel in the large B-cell lymphoma and has an option to develop up to three other ca...

                            Brand Name : PBCAR0191

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : $29.0 million

                            August 15, 2023

                            Lead Product(s) : Azercabtagene Zapreleucel,Fludarabine Phosphate,Cyclophosphamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Precision BioSciences

                            Deal Size : $662.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Imugene

                            Australia arrow
                            2024 ACI Convention
                            Not Confirmed

                            Imugene

                            Australia arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oncolytic Virus Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Recipient : RenovoRx

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arteria...

                            Details : The collaboration aims to optimize the delivery of Imugene’s oncolytic virus therapy with RenovoRx’s TAMP (Trans-Arterial Micro-Perfusion) therapy platform for the treatment of difficult-to-access tumors.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            July 20, 2023

                            Lead Product(s) : Oncolytic Virus Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Recipient : RenovoRx

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Imugene

                            Australia arrow
                            2024 ACI Convention
                            Not Confirmed

                            Imugene

                            Australia arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CF33-CD19,Blinatumomab

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FDA Clears Imugene IND To Commence onCARlytics First-In-Class Clinical Study

                            Details : onCARlytics (CF33-CD19, HOV4) is a live, attenuated oncolytic orthopox (vaccinia) virus engineered to encode a truncated human CD19 transgene, resulting in expression of de novo CD19 at the tumour cell surface before virus-mediated tumour cell lysis.

                            Brand Name : onCARlytics

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 19, 2023

                            Lead Product(s) : CF33-CD19,Blinatumomab

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Imugene

                            Australia arrow
                            2024 ACI Convention
                            Not Confirmed

                            Imugene

                            Australia arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CF33-hNIS,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : City of Hope

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Imugene And City Of Hope Announce First Patient Dosed In Phase 1 Trial To Test Cancer-Killing Oncolytic Virus ...

                            Details : City of Hope exclusively licensed patent rights covering Vaxina (CF33) to Imugene Limited, a company developing novel therapies that activate the immune system against cancer. Imugene has given CF33-hNIS the name Vaxinia.

                            Brand Name : Vaxina

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            May 18, 2022

                            Lead Product(s) : CF33-hNIS,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : City of Hope

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth